400客服电话
购买数据产品
400-9696-311 转1
定制咨询业务
400-9696-311 转2
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
ChiCTR2500114608
正在进行
/
/
/
2025-12-15
/
/
Liver cancer
Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study
Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study
To evaluate the efficacy of biomimetic 3D bioprinting technology in guiding the selection of optimal adjuvant treatment regimens to prevent hepatocellular carcinoma (HCC) recurrence after curative liver resection.
病例研究
其它
None
/
None
/
20
/
2025-12-15
2030-12-31
/
1. Age >= 18 years at the time of screening; 2.Diagnosis of HCC; 3.Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 4. With or without prior locoregional therapy such as transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT) before surgery; 5.Meet any item indicating higher risk of tumour recurrence: any tumour size >= 5cm, number of tumour >= 3, presence of microvascular or marcovascular invasion, or poor tumour differentiation; 6.No prior systemic therapy for HCC; 7. No other active malignancies within 5 years, except malignancies with a negligible risk of metastasis or death (eg. 5-year overall survival rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer; 8. Willing and able to provide written informed consent for the collection and usage of biological samples.；
请登录查看1.Non-HCC diagnosis, including fibrolamellar HCC, sarcomatoid HCC, mixed HCC cholangiocarcinoma etc; 2.Fail to give consent or refusal to take part in the study; 3.Child-Pugh class C liver cirrhosis; 4.Receipt of any prior systemic therapy for HCC.；
请登录查看Department of Surgery, The University of Hong Kong
/
德琪医药2026-07-20
动脉网-最新2026-07-20
药精通Bio2026-07-20
求实药社2026-07-20
求实药社2026-07-20
康方生物Akeso2026-07-20
干细胞与外泌体2026-07-20
加科思2026-07-20
良医汇肿瘤资讯2026-07-19
GLP1减重宝典2026-07-19
400-9696-311 转1
400-9696-311 转3
400-9696-311 转4
400-9696-311 转5
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
“坚决打赢禁毒人民战争”专栏 法律法规 | 美、墨、欧盟管制品种
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
